GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

PURE Biosciences PURE · USD

Consumer Staples · US listing · 🇺🇸 United States

Compare

0.07

+6.28%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$2.2m

FY2016FY2025

Net income

−$2.4m

FY2016FY2025

Free cash flow

−$2.0m

FY2016FY2025

Shareholders' equity

−$5.1m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$2.2m$2.0m$1.9m$1.9m$3.9m$6.9m$1.9m$1.8m$1.8m$1.3m
Gross profit$1.3m$1.2m$971,000$1.0m$2.1m$4.0m$1.2m$1.0m$1.1m$848,000
Research and development$316,000$302,000$297,000$319,000$339,000$322,000$354,000$459,000$779,000$927,000
Operating income−$2.3m−$3.1m−$3.9m−$3.4m−$2.3m$9,000−$5.6m−$7.0m−$6.0m$247,000
Net income−$2.4m−$3.4m−$4.0m−$3.5m−$2.3m−$6,000−$6.6m−$7.5m−$6.5m−$21.7m
Diluted earnings per share-0.02-0.03-0.04-0.03-0.03-0.00-0.08-0.11-0.10-0.33

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$1.1m$818,000$1.8m$4.5m$4.3m$6.3m$1.9m$2.6m$3.8m$7.6m
Cash and short-term investments$334,000$424,000$1.1m$3.4m$2.4m$3.8m$398,000$851,000$1.6m$5.2m
Total liabilities$6.2m$3.7m$1.6m$575,000$970,000$1.5m$742,000$1.3m$2.5m$2.5m
Debt$5.2m$2.9m$1.0m—$239,000——$503,000$1.9m$121,000
Shareholders' equity−$5.1m−$2.9m$272,000$3.9m$3.3m$4.8m$1.2m$1.3m$1.3m$5.0m
Shares outstanding112m112m112m111m87m87m78m71m65m65m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−$2.0m−$2.5m−$3.3m−$2.4m−$1.2m$669,000−$3.0m−$3.9m−$4.6m−$5.0m
Capital spending——−$33,000−$81,000−$521,000−$58,000−$13,000−$34,000−$226,000−$405,000
Free cash flow−$2.0m−$2.5m−$3.3m−$2.5m−$1.7m$611,000−$3.0m−$3.9m−$4.8m−$5.4m

Latest quarters

By quarter end

Apr 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024Jul 2024
Revenue$506,000$444,000$708,000$764,000$491,000$391,000$556,000$474,000
Gross profit$269,000$238,000$450,000$468,000$283,000$227,000$325,000$275,000
Operating income−$518,000−$683,000−$379,000−$336,000−$584,000−$725,000−$627,000−$639,000
Net income−$624,000−$785,000−$464,000−$332,000−$580,000−$798,000−$689,000−$756,000
Diluted earnings per share-0.01-0.01-0.00-0.00-0.01-0.01-0.01-0.01
Total assets$1.6m$788,000$1.2m$1.1m$1.1m$574,000$924,000$818,000
Cash and short-term investments———$334,000—$202,000$346,000$349,000
Debt$3.7m$4.0m$3.6m$5.2m$4.9m$4.0m$3.5m$2.9m
Shareholders' equity−$5.8m−$6.3m−$5.5m−$5.1m−$4.8m−$3.4m−$2.6m−$2.9m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue5.9%-20.5%11.7%
Operating income-12.8%—-11.4%
Net income-11.8%231.4%-10.9%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin58.9%56.1%56.2%57.4%
Operating margin-129.7%-161.8%-80.4%-156.5%
Net margin-138.0%-167.3%-82.9%-248.9%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-1.9-2.0-3.7-1.6-4.6-7203.3-2.2-2.3-6.0-1.7
Price to sales2.03.47.83.12.76.37.59.721.427.8

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return-17%-60%68%-36%-68%130%-30%-55%0%-2%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 8-to-1 reverse split · 15 Aug 2012
  • 1.02-for-1 split · 2 Nov 2000

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.